CalciMedica, Inc. (NASDAQ:CALC) shares are down on Wednesday after the company announced the discontinuation of its Phase 2 KOURAGE clinical trial.
The trial was evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). Data was expected in the first half of 2026.
The stock is trading lower with a session volume of 23.27 million, compared to the average volume of 84.063 thousand.
CalciMedica Halts KOURAGE Trial Due to Safety Concerns
CalciMedica decided to halt the trial after a recommendation from the Independent Data Monitoring Committee (IDMC). The IDMC identified safety concerns that necessitated a reevaluation of the study design, particularly regarding patient enrollment criteria.
There were no deaths in the trial. In addition, no serious adverse events met the criteria for expedited reporting to the U.S. Food and Drug Administration (FDA).
The company plans to conduct a comprehensive review of the unblinded clinical data to inform future clinical evaluations of its product candidate, Auxora.
In addition, CalciMedica has notified the FDA about the trial’s discontinuation and is working with investigators to ensure that all patients currently enrolled complete their follow-up.
The company remains optimistic about Auxora’s potential in treating acute inflammatory illnesses and is looking to finalize the design of a pivotal trial in acute pancreatitis in the first half of 2026.
Rachel Leheny, CEO of CalciMedica, said, “To date, no treatment-related safety concern has been observed across more than 350 critically ill patients treated with Auxora in completed clinical trials, including the Phase 2b CARPO trial in acute pancreatitis (AP) and the Phase 2 CARDEA trial in severe COVID-19 pneumonia.”
CalciMedica Stock Plummets Below Key SMAs
CalciMedica’s stock is currently trading 83.5% below its 20-day simple moving average (SMA) and 77% below its 100-day SMA, indicating significant weakness in its price action. Over the past 12 months, shares have declined by approximately 65.68%. They are currently near their 52-week lows rather than their highs, reflecting ongoing challenges for the company.
The RSI is at 46.35, which is considered neutral territory, while the MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum, pointing to a lack of clear direction in the stock’s performance.
- Key Resistance: $1.50
- Key Support: $0.50
CalciMedica Scores High on Momentum: Benzinga Edge
Below is the Benzinga Edge scorecard for CalciMedica, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Strong (Score: 91.08) — Stock is outperforming the broader market.
The Verdict: CalciMedica’s Benzinga Edge signal reveals a classic “High-Flyer” setup. While the momentum (91.08) confirms the strong trend, the lack of other rankings indicates potential vulnerabilities that investors should monitor closely.
CalciMedica Shares Tumble to $0.99
CALC Price Action: CalciMedica shares were down 80.66% at $0.99 at the time of publication on Wednesday, according to Benzinga Pro data.
Image: Shutterstock
